142 related articles for article (PubMed ID: 36872899)
21. Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
Feng Z; Miao Y; Peng Y; Sun F; Zhang Y; Li R; Ge S; Chen X; Song L; Li Y; Wang X; Zhang W
BMC Infect Dis; 2023 May; 23(1):300. PubMed ID: 37158831
[TBL] [Abstract][Full Text] [Related]
22. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
Velayutham BV; Allaudeen IS; Sivaramakrishnan GN; Perumal V; Nair D; Chinnaiyan P; Paramasivam PK; Dhanaraj B; Santhanakrishnan RK; Navaneethapandian GP; Marimuthu MK; Kumar V; Kandasamy C; Dharuman K; Elangovan T; Narasimhan M; Rathinam S; Vadivelu G; Rathinam P; Chockalingam C; Jayabal L; Swaminathan S; Shaheed JM
Clin Infect Dis; 2014 Nov; 59(10):e142-9. PubMed ID: 25028463
[TBL] [Abstract][Full Text] [Related]
23. Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.
Hagiwara E; Suido Y; Asaoka M; Katano T; Okuda R; Sekine A; Kitamura H; Baba T; Komatsu S; Ogura T
J Infect Chemother; 2019 Dec; 25(12):1026-1030. PubMed ID: 31229376
[TBL] [Abstract][Full Text] [Related]
24. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
Dalcolmo M; Gayoso R; Sotgiu G; D'Ambrosio L; Rocha JL; Borga L; Fandinho F; Braga JU; Galesi VM; Barreira D; Sanchez DA; Dockhorn F; Centis R; Caminero JA; Migliori GB
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331044
[TBL] [Abstract][Full Text] [Related]
26. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
[TBL] [Abstract][Full Text] [Related]
27. [Pyrazinamide-containing initial intensive short course chemotherapy of pulmonary tuberculosis].
Wada M
Kekkaku; 1997 Oct; 72(10):587-95. PubMed ID: 9386358
[TBL] [Abstract][Full Text] [Related]
28. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
Lee JK; Lee JY; Kim DK; Yoon HI; Jeong I; Heo EY; Park YS; Jo YS; Lee JH; Park SS; Park JS; Kim J; Lee SM; Joh JS; Lee CH; Lee J; Choi SM; Park JH; Lee SH; Cho YJ; Lee YJ; Kim SJ; Kwak N; Hwang YR; Kim H; Ki J; Lim JN; Choi HS; Lee M; Song T; Kim HS; Han J; Ahn H; Hahn S; Yim JJ
Lancet Infect Dis; 2019 Jan; 19(1):46-55. PubMed ID: 30477961
[TBL] [Abstract][Full Text] [Related]
29. Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.
Ruan Q; Liu Q; Sun F; Shao L; Jin J; Yu S; Ai J; Zhang B; Zhang W
Emerg Microbes Infect; 2016 Feb; 5(2):e12. PubMed ID: 26905025
[TBL] [Abstract][Full Text] [Related]
30. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Hutchings J; Burger DA; Schall R; Mendel CM
Am J Respir Crit Care Med; 2015 Apr; 191(8):943-53. PubMed ID: 25622149
[TBL] [Abstract][Full Text] [Related]
31. Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).
Ekqvist D; Bornefall A; Augustinsson D; Sönnerbrandt M; Nordvall MJ; Fredrikson M; Carlsson B; Sandstedt M; Simonsson USH; Alffenaar JC; Paues J; Niward K
BMJ Open; 2022 Mar; 12(3):e054788. PubMed ID: 35273049
[TBL] [Abstract][Full Text] [Related]
32. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
[TBL] [Abstract][Full Text] [Related]
34. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
[TBL] [Abstract][Full Text] [Related]
35. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
[TBL] [Abstract][Full Text] [Related]
36. Standard therapy for tuberculosis 1985.
Snider DE; Cohn DL; Davidson PT; Hershfield ES; Smith MH; Sutton FD
Chest; 1985 Feb; 87(2 Suppl):117S-124S. PubMed ID: 3881230
[TBL] [Abstract][Full Text] [Related]
37. A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
S Afr Med J; 1996 Aug; 86(8):960-5. PubMed ID: 8823423
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary tuberculosis treated with isoprodian and rifampicin or pyrazinamide.
Kleeberg HH
Chemotherapy; 1987; 33(3):219-28. PubMed ID: 3297528
[TBL] [Abstract][Full Text] [Related]
39. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
Su WJ; Perng RP
Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
[TBL] [Abstract][Full Text] [Related]
40. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
Cook PP; Maldonado RA; Yarnell CT; Holbert D
Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]